| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.venusremedies.com | |
| Financial Indicators | ||
|---|---|---|
| Market Cap | 621.03 Cr. | |
| Earnings per share (EPS) | 46.21 | Trailing Twelve Months Ending 2021-03 |
| Price-Earning Ratio (PE) | 10.05 | Trailing Twelve Months Ending 2021-03 |
| Industry PE | 35.17 | Trailing Twelve Months Ending 2021-03 |
| Book Value / Share | 309.75 | Trailing Twelve Months Ending 2021-03 |
| Price to Book Value | 1.50 | Calculated using Price: 464.60 |
| Dividend Yield | 0.00 | Period Ending 2020-03 |
| No. of Shares Subscribed | 1.34 Cr. | 13,366,988 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Venus Remedies incorporated in 1989, is a pharmaceutical manufacturing company. The company provides formulations in area of anti-biotics and oncological therapeutics. Company has two manufacturing facilities located in India and Germany. Company manufactures Oncological and Cefelosporine Injectable products. Its manufacturing facility located in India has received ISO 9001, ISO, 14001 and OHSAS 18001 for quality management. Its Germany facility follows EU-GMP norms. Presently, the company has successfully made its presence in the markets of Philippines, Thailand, Malaysia, Cambodia, Burma, Vietnam, Sri Lanka, Pakistan, Bangladesh, Nepal, Uganda, Kenya, Botswana, Zimbabwe, Sudan, Mauritius, Yemen, Iraq, Russia, Belarus, Ukraine, Costa Rica, Venezuela, Guatemala, Peru, Colombia, Ecuador, Syria, Yeman, Togo, Saudi Arbia and Iraq. Company has entered into strategic alliances with various pharmaceutical companies to launch its R&D based specialty products. It has tie-ups with companies namely IPCA Laboratories, Elder Pharmaceuticals, Shreya Lifesciences, Cadila Healthcare, Glenmark Pharmaceuticals, Marksans Pharma, Indoco Remedies, Karle Health Sciences, Lupin and Jagsonpal Pharmaceuticals. Company also conducts in-house research and development activities that focuses Formulation Development, NDDS (Novel Drug Delivery System), new formulations of off patented chemicals and analytical and chemical research. Products The company is engaged in manufacturing products catering various segments such as Oncology, Cephalosporins, Carbapenems and Other Specialties, Intravenous Products, Vials/Lyophilized Injectables, Pre-Filled Syringes, Hormones, Ampoules and Biological Products. Milestone/ Awards 2009 |
||
Company Profile
Venus Remedies incorporated in 1989, is a pharmaceutical manufacturing company. The company provides formulations in area of anti-biotics and oncological therapeutics.
Company has two manufacturing facilities located in India and Germany. Company manufactures Oncological and Cefelosporine Injectable products.
Its manufacturing facility located in India has received ISO 9001, ISO, 14001 and OHSAS 18001 for quality management. Its Germany facility follows EU-GMP norms.
Presently, the company has successfully made its presence in the markets of Philippines, Thailand, Malaysia, Cambodia, Burma, Vietnam, Sri Lanka, Pakistan, Bangladesh, Nepal, Uganda, Kenya, Botswana, Zimbabwe, Sudan, Mauritius, Yemen, Iraq, Russia, Belarus, Ukraine, Costa Rica, Venezuela, Guatemala, Peru, Colombia, Ecuador, Syria, Yeman, Togo, Saudi Arbia and Iraq.
Company has entered into strategic alliances with various pharmaceutical companies to launch its R&D based specialty products. It has tie-ups with companies namely IPCA Laboratories, Elder Pharmaceuticals, Shreya Lifesciences, Cadila Healthcare, Glenmark Pharmaceuticals, Marksans Pharma, Indoco Remedies, Karle Health Sciences, Lupin and Jagsonpal Pharmaceuticals.
Company also conducts in-house research and development activities that focuses Formulation Development, NDDS (Novel Drug Delivery System), new formulations of off patented chemicals and analytical and chemical research.
Products
The company is engaged in manufacturing products catering various segments such as Oncology, Cephalosporins, Carbapenems and Other Specialties, Intravenous Products, Vials/Lyophilized Injectables, Pre-Filled Syringes, Hormones, Ampoules and Biological Products.
Milestone/ Awards
2009
Venus Remedies - Product Patent for "TOBRACEF" granted in South Africa.
Venus Bags Another Product Patent from South Africa for POTENTOX.
2010
Venus Remedies receives GMP Certification from Botswana".
Venus Remedies ties up with IMTECH and Panjab Univ to develop Typhoid detection kits.
The Company has received approval from the Reserve Bank of India for rollover of FCCB USD 5mn, with YTM @4% with maturity till February 15, 2015.
Venus Remedies research Blockbuster "Sulbactomax" gets European Union Patent"
2011
Venus Remedies Ltd wins Gold Medal for TROIS under DST - Lockheed Martin India Innovation Growth Program 2011.
Venus launches its patented research product ACHNIL” in India.
Venus Remedies wins ""India Manufacturing Excellence Award 2011.
2012
Venus Remedies introduces "Ready-to-Use"" Single Vial Taxedol in India
Venus Remedies Limited introduced TROIS that is a research based, patent protected topical nano-emulsion product in India
The Company has won Manufacturing Award for its world class manufacturing and operational excellence at the "Industry 2.0 Manufacturing Innovation Conclave 2012.
Venus wins Patent award in Silver Category.
| 1 Day |
|
-1.13% |
| 1 Week |
|
+0.98% |
| 1 Month |
|
+39.65% |
| 3 Month |
|
+39.23% |
| 6 Month |
|
+181.52% |
| 1 Year |
|
+544.25% |
| 2 Year |
|
+2090.76% |
| 5 Year |
|
+435.63% |
| 9 years | 2012-03 | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | |
| Return on Equity (%) | 17.73 | 17.04 | 15.38 | 1.12 | 0.38 | -4.13 | -8.18 | -8.23 | -3.05 | |
| Return on Capital Employed (%) | 16.47 | 14.85 | 14.06 | 5.74 | 5.35 | 2.00 | 1.17 | -0.67 | 0.90 | |
| Return on Assets (%) | 9.10 | 8.87 | 8.29 | 0.62 | 0.20 | -2.12 | -4.05 | -3.85 | -1.46 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Shh. Funds | 307 | 379 | 462 | 457 | 438 | 389 | 362 | 333 | 323 | |
| Non Curr. Liab. | 114 | 147 | 162 | 222 | 212 | 180 | 158 | 137 | 96 | |
| Curr. Liab. | 153 | 191 | 211 | 163 | 193 | 197 | 230 | 264 | 219 | |
| Minority Int. | ||||||||||
| Equity & Liab. | 574 | 718 | 834 | 841 | 843 | 765 | 751 | 733 | 638 | |
| Non Curr. Assets | 404 | 492 | 562 | 608 | 566 | 506 | 491 | 467 | 350 | |
| Curr. Assets | 170 | 226 | 272 | 233 | 277 | 259 | 260 | 265 | 288 | |
| Misc. Exp. not W/O | ||||||||||
| Total Assets | 574 | 718 | 834 | 841 | 843 | 765 | 751 | 733 | 638 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Net Sales | 410 | 469 | 542 | 464 | 418 | 400 | 372 | 322 | 341 | |
| Other Income | 0 | 0 | 0 | 1 | 2 | 4 | 2 | 6 | 5 | |
| Total Income | 410 | 469 | 542 | 465 | 420 | 404 | 375 | 328 | 347 | |
| Total Expenditure | -307 | -349 | -403 | -375 | -337 | -349 | -333 | -289 | -301 | |
| PBIDT | 103 | 121 | 139 | 90 | 83 | 55 | 42 | 39 | 46 | |
| Interest | -27 | -25 | -29 | -41 | -38 | -36 | -36 | -25 | -13 | |
| Depreciation | -25 | -33 | -40 | -46 | -42 | -40 | -34 | -34 | -32 | |
| Taxation | -4 | -6 | -5 | 3 | -2 | 5 | -3 | 1 | -2 | |
| Exceptional Items | -9 | -9 | ||||||||
| PAT | 47 | 57 | 64 | 5 | 2 | -17 | -31 | -29 | -10 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Cash Fr. Operatn. | 42 | 52 | 53 | 68 | 47 | 59 | 31 | 45 | 77 | |
| Cash Fr. Inv. | -95 | -104 | -95 | -67 | 3 | -18 | -11 | -11 | -5 | |
| Cash Fr. Finan. | 53 | 55 | 40 | -1 | -46 | -44 | -39 | -35 | -73 | |
| Net Change | 0 | 3 | -2 | -1 | 3 | -4 | -20 | -1 | -1 | |
| Cash & Cash Eqvt | 3 | 6 | 4 | 4 | 7 | 4 | -20 | 3 | 2 |
|
Mon, 19 Jul 2021
RELEASE OF ENTIRE ENCUMBRANCE ON PROMOTERS' SHARES This has reference to our letter dated 19.07.2021 regarding disclosure under Regulation 31(1) & 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations 2011 regarding release of encumbrance on 8 30 000 equity shares of promoters. Now in furtherance to above said letter we wish to inform our esteemed shareholders that with the said release the entire shareholding of the promoters & promoter group is now free from all encumbrances. |
|
Mon, 19 Jul 2021
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on July 19 2021 for Pawan Chaudhary & Mrs Manu Chaudhary |
|
Fri, 16 Jul 2021
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Compliance under Regulation 39(3) of SEBI (LODR) Regulations 2015. |
| Fri, 23 Jul 2021 |
Stock Outperforming Benchmark Index in both 1 Week and 3 Month
|
Stock Outperforming Sectoral Index in both 1 Week and 3 Month
|
Strongly Outperforming Benchmark Index
|
Strongly Outperforming Sectoral Index
|
Close Within 2 Year High Zone
|
Equities
M.F.
Sectors